Compare HOG & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOG | BHC |
|---|---|---|
| Founded | 1903 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | N/A | N/A |
| Metric | HOG | BHC |
|---|---|---|
| Price | $20.46 | $6.96 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $28.00 | $8.67 |
| AVG Volume (30 Days) | ★ 2.9M | 2.1M |
| Earning Date | 02-04-2026 | 02-18-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.04 | 0.97 |
| Revenue | $4,664,627,000.00 | ★ $10,029,000,000.00 |
| Revenue This Year | N/A | $6.81 |
| Revenue Next Year | $2.04 | $4.11 |
| P/E Ratio | ★ $5.07 | $7.19 |
| Revenue Growth | N/A | ★ 5.86 |
| 52 Week Low | $20.40 | $4.25 |
| 52 Week High | $31.25 | $8.69 |
| Indicator | HOG | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 26.14 | 52.73 |
| Support Level | $20.51 | $6.74 |
| Resistance Level | $21.17 | $7.25 |
| Average True Range (ATR) | 0.52 | 0.22 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 1.52 | 41.54 |
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring categories, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 37% of the heavyweight domestic market in 2024.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.